|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
The Effect of Metastasis-Directed Therapy (MDT) on Oligometastatic Castration-Sensitive Prostate Cancer Outcomes
|
Philip Sutera, MD
In a conversation with Alicia Morgans, Phillip Sutera discusses his work in metastasis-directed therapy among patients with oligometastatic castration-sensitive prostate cancer. |
|
|
|
|
|
|
|
|
|
|
|
First Standardized Framework Measuring PSMA PET/CT Response in Metastatic Castration‑Resistant Prostate Cancer
|
Andrei Gafita, MD and Wolfgang Fendler, MD
Wolfgang Fendler and Andrei Gafita discuss the publication, "Measuring response in metastatic castration‑resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria".
|
|
|
|
|
|
|
|
|
|
|
|
Phenotypic Expression of Prostate Specific Membrane Antigen
|
|
Evan Yu, MD
|
Phillip Koo and Evan Yu discuss the phenotypic expression of PSMA in looking at the molecular characteristics of a tumor to identify the optimal personalized treatment for the patient.
|
|
|
|
|
|
|
|
|
|
|
|
| PSMA PET and FDG PET as Predictors of Response and Prognosis in a Randomized Phase 2 Trial of 177Lu-PSMA-617 Versus Cabazitaxel in mCRPC Progressing after Docetaxel: TheraP ANZUP 1603
|
| Michael S. Hofman, MBBS, FRACP
|
| In this presentation, Michael Hofman discusses PSMA PET and FDG PET as predictors of response and prognosis in the TheraP trial.
|
|
|
|
|
|
| PSMA PET Response Associates With rPFS Following Stereotactic Ablative Radiation Therapy in Oligometastatic Castration-Sensitive Prostate Cancer |
| Philip Sutera, MD |
| Philip Sutera discusses the association of PSMA response and radiographic-progression free survival among patients treated with stereotactic ablative radiation therapy in oligometastatic castration-sensitive prostate cancer. |
|
|
|
|
|
|
|
|
|
|
Randomized Prospective Phase III Trial of 68Ga-PSMA-11 PET/CT Molecular Imaging for Prostate Cancer Salvage Radiotherapy Planning [PSMA-SRT] - Beyond the Abstract
|
| Jeremie Calais, MD, MSc, |
| The lack of sensitivity of standard-of-care imaging for recurrent PCa combined with a sensitive and specific biomarker of early disease recurrence (serum PSA level) generates a unique challenge for local treatment of PCa BCR: cancer is present, but we do not know where it is. There is an unmet clinical need to improve target delineation in patients with potentially curable PCa with early BCR. |
|
|
|
|
|
| An Update on Radiographic Imaging for Detecting and Staging Prostate Cancer, Evaluating Treatment Response, and as a Prognostic and Predictive Biomarker |
| Phillip J. Koo, MD |
| This article provides an update on radiographic imaging for detecting and staging prostate cancer, evaluating treatment response, and as a prognostic and predictive biomarker. |
|
|
|
|
|
| Biomarker Testing in the Era of Novel Therapeutics
|
| Himisha Beltran, MD
|
| Himisha Beltran discusses biomarker testing in the era of novel therapeutics. She begins her presentation with the challenges of biomarker testing in the era of novel therapeutics is that PSMA. |
|
|
|
|
|
|
